PRESSEPORTAL Presseportal Logo

plus de sujets

Actualités de Dublin

Filtre
  • 14.11.2012 – 13:03

    Shire Pharmaceuticals Group Plc

    BRAVE Awards Recipients Announced

    Dublin (ots/PRNewswire) - - Fifteen everyday heroes who selflessly care for others in the face of adversity honored by Shire in annual international awards program They inspire with their determination, selflessness, courage and hope. Fifteen caregivers from around the world have been announced today as Recipients or Distinguished Honorees in the 2nd Annual Shire BRAVE Awards, an international program that honors the bravery and devotion of non-professional caregivers. ...

    plus
  • 12.04.2012 – 17:48

    Shire Pharmaceuticals Group Plc

    Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012

    Dublin (ots/PRNewswire) - Shire plc , the global specialty biopharmaceutical company, will announce first quarter 2012 earnings on Thursday April 26, 2012. Results press release will be issued at: 12:00 BST / 07:00 EDT Investor conference call time: 14:00 BST / 09:00 EDT Live conference call for investors: Angus Russell, Chief Executive Officer and Graham Hetherington, ...

    plus
  • 12.04.2012 – 15:12

    Shire Pharmaceuticals Group Plc

    Shire Adds new Technology Platform and Phase 2 Product Candidate to its Regenerative Medicine Business

    Dublin (ots/PRNewswire) - Shire plc , the global specialty biopharmaceutical company, today announced that it has signed an agreement to acquire substantially all the assets of Pervasis Therapeutics. Shire will provide Pervasis with an upfront payment, plus potential post-closing milestone payments that are dependent on Shire's achievement of certain clinical ...

    plus
  • 15.03.2012 – 12:01

    Shire Pharmaceuticals Group Plc

    Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment

    Dublin (ots/PRNewswire) - ? Shire plc , the global specialty biopharmaceutical company, announces that it has signed an agreement to acquire FerroKin BioSciences, Inc., for an upfront payment of $100 million, payable in cash at closing, plus potential post-closing milestone payments of up to $225 million, depending upon the achievement of certain clinical development, ...

    plus